Corteva is transforming from ag-chem heritage into IP-led “software for agriculture”—with a 2026 split and royalty neutrality poised to unlock a valuation re-rating, but dicamba and deal execution are the swing risks.
Overview
Corteva is positioned as the leading global pure-play ag-technology company, combining advanced seed genetics/traits with specialized crop protection. Since its 2019 spin from DowDuPont, it has concentrated R&D and commercial capabilities to address structural needs: food security, climate resilience, and sustainable farming. The business is organized into Seed (~57% of FY2025 revenue; ~$9.9B) and Crop Protection (~44%; ~$7.8B), generating total net sales of ~$17.4B, with a geographically diversified footprint led by North America (50%+ of sales) and meaningful exposure to Latin America (notably Brazil), EMEA, and Asia Pacific. Seed is anchored by Pioneer/Brevant brands and trait platforms that deliver yield, insect resistance, herbicide tolerance, and stress tolerance; Crop Protection spans herbicides/fungicides/insecticides and is expanding aggressively into biologicals—now the fastest-growing sub-segment. Customers are commercial growers in fundamentally non-discretionary end markets (food/feed and increasingly fuel), with emerging opportunities in SAF/renewable diesel via the Etlas JV. Competitive differentiation comes from an integrated “system” approach and a high-touch direct distribution network that builds loyalty, increases switching costs, and supports premium pricing via superior ROI per acre.